General Information of Drug (ID: DM5L7D3)

Drug Name
[3H]oxotremorine-M Drug Info
Synonyms
Oxotremorine M; oxotremorine-M; CHEBI:38322; N,N,N-trimethyl-4-(2-oxopyrrolidin-1-yl)but-2-yn-1-aminium; 63939-65-1; trimethyl-[4-(2-oxopyrrolidin-1-yl)but-2-ynyl]azanium; N,N,N-Trimethyl-4-(2-oxo-1-pyrrolidinyl)-2-butyn-1-aminium; 2-Butyn-1-aminium, N,N,N-trimethyl-4-(2-oxo-1-pyrrolidinyl)-; CHEMBL23957; Tocris-1067; Spectrum_001982; OXO-M; Lopac-O-100; AC1L1ILG; AC1Q6FK0; Lopac0_000954; GTPL303; KBioSS_002548; CHEMBL44674; DivK1c_000379; SCHEMBL4542695; GTPL8595; KBio2_005107; KBio2_002539; KBio1_000379
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
4629
ChEBI ID
CHEBI:38322
CAS Number
CAS 63939-65-1
TTD Drug ID
DM5L7D3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetylcholine DMDF79Z Cataract 9B10 Approved [5]
Tiotropium DMFDC0Q Chronic obstructive pulmonary disease CA22 Approved [6]
Darifenacin DMWXLYZ Overactive bladder GC50.0 Approved [7]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [8]
Clidinium DMUMQZ0 Abdominal stomach pain DD91.4 Approved [9]
Oxybutynin hydrochloride DMF2KLU Urinary incontinence MF50.2 Approved [10]
Incruse Ellipta DM32GSJ Chronic obstructive pulmonary disease CA22 Approved [11]
Revefenacin DMMP5SI Chronic obstructive pulmonary disease CA22 Approved [12]
Scopolamine DMOM8AL Addictive disorder 6C50-6C5Z Approved [13]
Isopropamide iodide DMQYV60 Allergic rhinitis CA08.0 Approved [14]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tolterodine DMSHPW8 Overactive bladder GC50.0 Approved [15]
ACECLIDINE DMOLNCZ Glaucoma/ocular hypertension 9C61 Approved [16]
Tiotropium DMFDC0Q Chronic obstructive pulmonary disease CA22 Approved [17]
Ipratropium DMFQ320 Obstructive lung disease CA22.Z Approved [18]
Darifenacin DMWXLYZ Overactive bladder GC50.0 Approved [19]
Methacholine Chloride DMGS4QH Asthma CA23 Approved [20]
SMT-D002 DM1I93C Seborrhea ED91.2 Approved [21]
Solifenacin DMG592Q Overactive bladder GC50.0 Approved [22]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [23]
Cevimeline DMWSMND Sjogren syndrome 4A43.20 Approved [24]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [2]
Carbachol DMX9K8F Glaucoma/ocular hypertension 9C61 Approved [25]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [26]
Panobinostat DM58WKG Chronic graft versus host disease Approved [27]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [28]
Testosterone DM7HUNW Hot flushes GA30 Approved [29]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [29]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [30]
Acetylcholine DMDF79Z Cataract 9B10 Approved [31]
Atropine DMEN6X7 Organophosphate poisoning NE6Z Approved [31]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Affected By Protein c-Fos (FOS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [32]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [33]
Verapamil DMA7PEW Angina pectoris BA40 Approved [34]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [35]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [34]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [36]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [37]
Methotrexate DM2TEOL Anterior urethra cancer Approved [38]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [39]
Quercetin DM3NC4M Obesity 5B81 Approved [40]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Paxillin (PXN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [41]
Quercetin DM3NC4M Obesity 5B81 Approved [42]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [43]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [44]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [45]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [46]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [47]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [48]
Cholecalciferol DMGU74E Adult acute monocytic leukemia Approved [49]
Terbinafine DMI6HUW Fungal infection 1F29-1F2F Approved [50]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [51]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [52]
Quercetin DM3NC4M Obesity 5B81 Approved [53]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [46]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [54]
Benzatropine DMF7EXL Parkinsonian disorder Approved [55]
Clozapine DMFC71L Schizophrenia 6A20 Approved [55]
Azathioprine DMMZSXQ Lupus nephritis 4A40.0Y Approved [56]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [57]
Arsenic DMTL2Y1 N. A. N. A. Approved [58]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Focal adhesion kinase 1 (PTK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [59]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [60]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [61]
Quercetin DM3NC4M Obesity 5B81 Approved [62]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [63]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [64]
Testosterone DM7HUNW Hot flushes GA30 Approved [65]
Halothane DM80OZ5 Anaesthesia 9A78.6 Approved [66]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [67]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [68]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ALCURONIUM DM2U4XQ Anaesthesia 9A78.6 Approved [69]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [54]
Acetylcholine DMDF79Z Cataract 9B10 Approved [70]
Atropine DMEN6X7 Organophosphate poisoning NE6Z Approved [69]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [71]
DTI-015 DMXZRW0 Brain cancer 2A00 Approved [72]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [2]
Carbachol DMX9K8F Glaucoma/ocular hypertension 9C61 Approved [2]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [73]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [74]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pirenzepine DMP6M1N Peptic ulcer DA61 Approved [75]
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [76]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [77]
Acetylcholine DMDF79Z Cataract 9B10 Approved [78]
Atropine DMEN6X7 Organophosphate poisoning NE6Z Approved [31]
Clozapine DMFC71L Schizophrenia 6A20 Approved [79]
Olanzapine DMPFN6Y Bipolar depression Approved [80]
Gallamine Triethiodide DMPO0MS Stabilize muscle contraction FB3Z Approved [81]
Carbachol DMX9K8F Glaucoma/ocular hypertension 9C61 Approved [78]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [2]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [82]
Gallamine Triethiodide DMPO0MS Stabilize muscle contraction FB3Z Approved [82]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [33]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [26]
Acetylcholine DMDF79Z Cataract 9B10 Approved [70]
Omadacycline DMR2J95 Acute bacterial skin infection 1C41 Approved [83]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [84]
Carbachol DMX9K8F Glaucoma/ocular hypertension 9C61 Approved [2]
Bardoxolone methyl DMODA2X Mixed connective tissue disease 4A43.3 Phase 3 [85]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [73]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor (CHRM) TTOXS3C NOUNIPROTAC Agonist [2]
Muscarinic acetylcholine receptor M3 (CHRM3) TTQ13Z5 ACM3_HUMAN Agonist [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Breast cancer anti-estrogen resistance protein 1 (BCAR1) OTKT2C2N BCAR1_HUMAN Post-Translational Modifications [3]
Focal adhesion kinase 1 (PTK2) OT3Q1JDY FAK1_HUMAN Post-Translational Modifications [3]
Muscarinic acetylcholine receptor M1 (CHRM1) OTKW3E6B ACM1_HUMAN Drug Response [2]
Muscarinic acetylcholine receptor M2 (CHRM2) OTUMZ2WR ACM2_HUMAN Drug Response [2]
Muscarinic acetylcholine receptor M3 (CHRM3) OTKSD095 ACM3_HUMAN Drug Response [2]
Muscarinic acetylcholine receptor M4 (CHRM4) OTF0F0FF ACM4_HUMAN Drug Response [2]
Paxillin (PXN) OTVMMUOF PAXI_HUMAN Post-Translational Modifications [3]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Gene/Protein Processing [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8595).
2 Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
3 Attenuation of focal adhesion kinase signaling following depletion of agonist-sensitive pools of phosphatidylinositol 4,5-bisphosphate. J Neurochem. 1999 Nov;73(5):1933-44.
4 Calcium signaling and c-Fos gene expression via M3 muscarinic acetylcholine receptors in human T- and B-cells. Jpn J Pharmacol. 2000 Oct;84(2):124-32. doi: 10.1254/jjp.84.124.
5 Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66.
6 Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013 May;345(2):260-70.
7 Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):177-84.
8 Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35.
9 Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J Pharmacol Exp Ther. 1998 Feb;284(2):500-7.
10 Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs. Nihon Yakurigaku Zasshi. 1999 Mar;113(3):157-66.
11 Clinical pipeline report, company report or official report of GlaxoSmithKline.
12 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
13 The amygdala modulates morphine-induced state-dependent memory retrieval via muscarinic acetylcholine receptors. Neuroscience. 2009 May 5;160(2):255-63.
14 Competitive and non-competitive antagonism exhibited by 'selective' antagonists at atrial and ileal muscarinic receptor subtypes. Br J Pharmacol. 1987 Apr;90(4):701-7.
15 Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53.
16 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
17 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
18 Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69.
19 M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5.
20 Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62.
21 Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
22 Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6.
23 Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94.
24 Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123.
25 Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway. Toxicol In Vitro. 2010 Oct;24(7):1953-61. doi: 10.1016/j.tiv.2010.08.005. Epub 2010 Aug 12.
26 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
27 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
28 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
29 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
30 Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
31 Assessment of false transmitters as treatments for nerve agent poisoning. Toxicol Lett. 2020 Mar 15;321:21-31. doi: 10.1016/j.toxlet.2019.12.010. Epub 2019 Dec 9.
32 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
33 Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
34 Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
35 Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
36 Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
37 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
38 Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther. 2014 Jan 20;16(1):R17. doi: 10.1186/ar4444.
39 Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
40 The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004 Jun 25;279(26):27008-16. doi: 10.1074/jbc.M403588200. Epub 2004 Apr 16.
41 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
42 Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
43 Small ubiquitin-related modifier-1 modification regulates all-trans-retinoic acid-induced differentiation via stabilization of retinoic acid receptor . FEBS J. 2014 Jul;281(13):3032-47. doi: 10.1111/febs.12840. Epub 2014 Jun 2.
44 Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
45 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
46 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
47 Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
48 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
49 Paxillin increases as retinoic acid or vitamin D3 induce HL-60 cell differentiation. In Vitro Cell Dev Biol Anim. 1997 Feb;33(2):84-7. doi: 10.1007/s11626-997-0027-0.
50 Terbinafine inhibits endothelial cell migration through suppression of the Rho-mediated pathway. Mol Cancer Ther. 2006 Dec;5(12):3130-8. doi: 10.1158/1535-7163.MCT-06-0457.
51 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
52 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
53 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
54 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
55 Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
56 A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
57 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
58 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
59 Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
60 Cleavage of focal adhesion kinase is an early marker and modulator of oxidative stress-induced apoptosis. Chem Biol Interact. 2008 Jan 10;171(1):57-66. doi: 10.1016/j.cbi.2007.08.009. Epub 2007 Aug 19.
61 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
62 Quercetin inhibits migration and invasion of SAS human oral cancer cells through inhibition of NF-B and matrix metalloproteinase-2/-9 signaling pathways. Anticancer Res. 2013 May;33(5):1941-50.
63 Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol. 2006 Oct;33(7):875-82. doi: 10.1016/j.nucmedbio.2006.07.004.
64 Activation of cannabinoid receptors promote periodontal cell adhesion and migration. J Clin Periodontol. 2019 Dec;46(12):1264-1272. doi: 10.1111/jcpe.13190. Epub 2019 Oct 22.
65 Monomeric and oligomeric flavanols are agonists of membrane androgen receptors. Exp Cell Res. 2005 Oct 1;309(2):329-39. doi: 10.1016/j.yexcr.2005.06.011.
66 Disruption of FAK signaling: a side mechanism in cytotoxicity. Toxicology. 2008 Mar 12;245(1-2):1-10. doi: 10.1016/j.tox.2007.12.003. Epub 2007 Dec 15.
67 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
68 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
69 Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors. Mol Pharmacol. 2006 Aug;70(2):736-46. doi: 10.1124/mol.106.024711. Epub 2006 May 18.
70 Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors. Life Sci. 1999;64(6-7):519-26. doi: 10.1016/s0024-3205(98)00596-7.
71 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
72 Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
73 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
74 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
75 Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor. J Med Chem. 2004 Aug 12;47(17):4300-15. doi: 10.1021/jm040800a.
76 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
77 Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in?vivo assays in mice. Neuropharmacology. 2016 Nov;110(Pt A):143-153. doi: 10.1016/j.neuropharm.2016.07.016. Epub 2016 Jul 20.
78 Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2355-63.
79 Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action. Neuroreport. 2002 May 7;13(6):831-5. doi: 10.1097/00001756-200205070-00019.
80 No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
81 Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Mol Pharmacol. 2000 Jul;58(1):194-207.
82 Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. Mol Pharmacol. 2006 Jul;70(1):181-93. doi: 10.1124/mol.106.023481. Epub 2006 Apr 26.
83 In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5247-53. doi: 10.1128/AAC.00320-16. Print 2016 Sep.
84 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
85 Characterization of the potent, selective Nrf2 activator, 3-(pyridin-3-ylsulfonyl)-5-(trifluoromethyl)-2H-chromen-2-one, in cellular and in vivo models of pulmonary oxidative stress. J Pharmacol Exp Ther. 2017 Oct;363(1):114-125.